Haloperidol
Butyrophenone Derivatives
- Drug class
- Butyrophenone Derivatives
- Availability
- Prescription only
- Routes
- Intramuscular, Oral
- Markets covered
- 3
- Products on record
- 50
- FDA reports (12 mo)
- 1,314
Overview
Haloperidol is an active pharmaceutical ingredient in the Butyrophenone Derivatives group (N05AD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 29 | May 29, 2026 |
| CA Canada | Health Canada | 14 | March 19, 2026 |
| US United States | FDA | 7 | April 8, 2026 |
GBUnited Kingdom· MHRA
29 products
Uses
Adult patients aged 18 years and above • Treatment of schizophrenia and schizoaffective disorder. • Acute treatment of delirium when non-pharmacological treatments have failed. • Treatment of moderate to severe manic episodes associated with bipolar I disorder.
• Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder. • Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer’s dementia and vascular dementia when non- pharmacological treatments have failed and when there is a risk of harm to self or others.
• Treatment of tic disorders, including Tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed. • Treatment of mild to moderate chorea in Huntington’s disease, when other medicinal products are ineffective or not tolerated.
Paediatric patients Treatment of: • Schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated. • Persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated.
CACanada· Health Canada
14 products
Side effects & warnings
TEVA-HALOPERIDOL (haloperidol) prolongs the hypnotic action of barbiturates and may potentiate the effects of alcohol and other central nervous system depressant drugs, such as anesthetics and narcotics; caution should therefore be exercised when it is used with agents of this type and adjustments in its dosage may be required.
Haloperidol may lower the convulsive threshold and has been reported to trigger seizures in previously controlled known epileptics. When instituting haloperidol therapy in these patients, adequate anticonvulsant medication should be maintained concomitantly.
Elderly or debilitated patients receiving the drug should be carefully observed for any evidence of oversedation which might lead to dehydration and reduced pulmonary ventilation and could result in complications, such as terminal bronchopneumonia.
USUnited States· FDA
7 products
Uses
INDICATIONS AND USAGE
Haloperidol tablets are indicated for use in the management of manifestations of psychotic disorders. Haloperidol tablets are indicated for the control of tics and vocal utterances of Tourette's Disorder in children and adults. Haloperidol tablets are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation).
Haloperidol tablets are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Haloperidol tablets should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.
Drug interactions
Known interactions involving Haloperidol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL002890305 · revised December 6, 2024
- [2]Health Canada (DPD) · 00363650 · revised March 22, 2025
- [3]FDA DailyMed · 00bb61c8-db35-4c… · revised November 15, 2024 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.